M-Edg looks to boost med-tech sector

Florida firm hopes to raise $50m. to convert Israeli incubators.

May 4, 2006 06:54
2 minute read.
john perry 88 298

john perry 88 298. (photo credit: Courtesy photo)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Israel's medical technology sector may be on the verge of getting a lift from a Florida company that sees the area as being largely untapped given the high level of innovation in the country. Medical-Enterprise Development Group (M-Edg), a management company in the health care industry, plans to launch Florida's First Coast - Israeli Initiative later this month, to raise $30 million to $50m. to help boost the commercialization of Israeli medical technology. The company will host an event in Florida on May 17 where it hopes to attract investors for the fund to take the project into the next phase of operation. "We are bringing to market a different model than that previously in place in Israel," John Perry, president of M-Edg told The Jerusalem Post during a recent visit to Israel. "Our focus is not on R&D but rather the next stage of the products development, helping the companies to grow and market their product." Perry explained that under the M-Edg model, Israeli incubator companies will gain one-third ownership in a new subsidiary, with the remaining two-thirds split equally between the US investors and M-Edg, which will be responsible for management of the company. "Typically, incubator companies enter into royalty and licensing agreements where they take about four percent of the sales of their products," Perry said. "We are offering the Israeli innovators up to 20-30% greater value on their projects." Perry said the model aims to bring Israeli products to market within one year, and then grow the company over a period of three years, before exiting with an IPO or a buy-out from an outside investor. It also could "possibly allow the Israeli partner to buy out the rest of the company," he added. Having first been exposed to Israeli R&D capabilities some 20 years ago through his involvement in the US Federation of Israeli Chambers of Commerce, Perry said he was well aware of the level of innovation in Israel and that, when at the end of 2005 M-Edg raised approximately $3.3m., the consensus was that Israel was the natural place to take the project. Through the company's representatives in Israel, business development company OBV, owned by Dan and Ariel Makov, Perry and the five other members of M-Edg senior management visited Israel in February and again in April and have met with approximately 40% of all the incubators to get them on board. "The combination of government support through the incubator program and the high level of education and innovation here have brought Israel to lead the world in bringing medical devices and information technology to the market," Perry said. "We are extremely strong in IT and in a good position to reconcile the sector with effective management, where we believe there is gap in the country's product development."

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection


Cookie Settings